Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Butowski · SciRah

Researcher profile · Semantic Scholar

N. Butowski

Share profile

N. Butowski — researcher profile on SciRah

h-index: 59
Works: 386
Citations: 14K

Most-cited papers

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
A. Omuro, A. Brandes, A. Carpentier, A. Idbaih +25 more
2022Neuro-Oncology471 citations Open access
Semantic Scholar
Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities
A. Choudhury, S. Magill, C. Eaton, B. Prager +32 more
2022Nature Genetics239 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
C. Horbinski, L. Nabors, J. Portnow, J. Baehring +33 more
2023The Journal of the National Comprehensive Cancer Network195 citations Open access
Semantic Scholar
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma
S. Hervey-Jumper, Yalan Zhang, J. Phillips, R. Morshed +32 more
2023Journal of Clinical Oncology126 citations Open access
Semantic Scholar
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
S. Venneti, A. Kawakibi, Sunjong Ji, Sebastian M. Waszak +80 more
2023Cancer Discovery115 citations Open access
Semantic Scholar
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Yao Yu, J. Villanueva-Meyer, M. Grimmer, S. Hilz +18 more
2021Neuro-Oncology92 citations Open access
Semantic Scholar
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
I. Arrillaga-Romany, Sharon L. Gardner, Y. Odia, D. Aguilera +26 more
2024Journal of Clinical Oncology68 citations Open access
Semantic Scholar
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
William C. Chen, A. Choudhury, Mark W. Youngblood, Mei-Yin C. Polley +54 more
2023Nature Medicine68 citations Open access
Semantic Scholar
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
A. Lassman, J. Sepúlveda-Sánchez, T. Cloughesy, M. Gil-Gil +16 more
2022Clinical Cancer Research66 citations Open access
Semantic Scholar
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
A. Omuro, D. Reardon, J. Sampson, J. Baehring +6 more
2022Neuro-Oncology Advances62 citations Open access
Semantic Scholar
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
H. Ogino, Jennie W. Taylor, Takahide Nejo, D. Gibson +21 more
2021Journal of Clinical Investigation57 citations Open access
Semantic Scholar
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1
C. Lucas, Emily A. Sloan, Rohit Gupta, Jasper Wu +38 more
2022Acta Neuropathologica42 citations Open access
Semantic Scholar
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
D. Raleigh, William Chen, A. Choudhury, Mark W. Youngblood +53 more
2023Research Square39 citations Open access
Semantic Scholar
“De novo replication repair deficient glioblastoma, IDH-wildtype” is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade
S. Hadad, Rohit Gupta, N. A. Oberheim Bush, Jennie W. Taylor +26 more
2023Acta Neuropathologica34 citations Open access
Semantic Scholar
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
J. Sarkaria, K. Ballman, S. Kizilbash, E. Sulman +20 more
2024JAMA Oncology32 citations Open access
Semantic Scholar
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial
J. Sampson, Achal Singh Achrol, M. Aghi, Krys Bankiewicz +19 more
2023Neuro-Oncology32 citations Open access
Semantic Scholar
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas.
Kwang-Soo Kim, K. Habashy, A. Gould, Jun-Fei Zhao +30 more
2024Neuro-Oncology31 citations Open access
Semantic Scholar
Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma
B. Ellingson, J. Sampson, A. Achrol, M. Aghi +17 more
2021Clinical Cancer Research29 citations Open access
Semantic Scholar
NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM.
Andrew E. Sloan, Kathryn A. Winter, M. Gilbert, K. Aldape +9 more
2024Neuro-Oncology28 citations
Semantic Scholar
Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes
Yalan Zhang, C. Lucas, Jacob S. Young, R. Morshed +23 more
2022Neuro-Oncology28 citations Open access
Semantic Scholar
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses
Calixto-Hope G. Lucas, N. Al-Adli, J. Young, Rohit Gupta +25 more
2024Neuro-Oncology27 citations Open access
Semantic Scholar
Intratumor and informatic heterogeneity influence meningioma molecular classification
H. Vasudevan, A. Choudhury, S. Hilz, J. Villanueva-Meyer +11 more
2022Acta Neuropathologica25 citations Open access
Semantic Scholar
Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect
D. Gibson, Akshay Ravi, E. Rodriguez, Susan M. Chang +11 more
2023Neuro-Oncology Advances22 citations Open access
Semantic Scholar
A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]
D. Gibson, A. Vo, Hannah Lambing, Prithanjan Bhattacharya +3 more
2024BMC Neurology19 citations Open access
Semantic Scholar
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
Atsuro Saijo, Hirokazu Ogino, N. Butowski, Meghan Tedesco +22 more
2023Neuro-Oncology19 citations Open access
Semantic Scholar
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
M. I. de la Fuente, Jordi Rodon Ahnert, R. Yaeger, F. Tsai +13 more
2023Journal of Clinical Oncology17 citations
Semantic Scholar
CDK 4/6 inhibitors for the treatment of meningioma
Jacob S. Young, Reilly L. Kidwell, Allison C. Zheng, Alexander F. Haddad +4 more
2022Frontiers in Oncology17 citations Open access
Semantic Scholar
Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis)
J. Rodriguez-Almaraz, N. Butowski
2023Current Treatment Options in Oncology16 citations Open access
Semantic Scholar
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
A. Sloan, R. Buerki, C. Murphy, A. Kelly +15 more
202116 citations
Semantic Scholar
Recent advances in the molecular prognostication of meningiomas
Elaina Wang, Alexander F. Haddad, Jacob S. Young, R. Morshed +4 more
2023Frontiers in Oncology15 citations Open access
Semantic Scholar
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
H. Fine, T. Reid, S. Caroen, B. Oronsky +2 more
2023Frontiers in Oncology9 citations Open access
Semantic Scholar
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
E. Galanis, S. Anderson, E. Twohy, N. Butowski +12 more
2022Neuro-Oncology Advances9 citations Open access
Semantic Scholar
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment
M. Mrugala, Q. Ostrom, S. Pressley, Jennie W. Taylor +24 more
2021Neuro-Oncology Advances9 citations Open access
Semantic Scholar
LTBK-09. RESULTS OF BMX-HGG STUDY: A MULTI-INSTITUTIONAL, RANDOMIZED PHASE 2 CLINICAL TRIAL OF CONCURRENT CHEMORADIATION WITH OR WITHOUT BMX-001 IN PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMA
K. Peters, Adam Cohen, N. Butowski, J. Villano +19 more
2023Neuro-Oncology8 citations Open access
Semantic Scholar
Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma
Anna F. Piotrowski, K. Shih, P. Giglio, H. Colman +7 more
2025Current Oncology6 citations Open access
Semantic Scholar
Novel intraoperative strategies for enhancing tumor control: Future directions
Alexander F. Haddad, M. Aghi, N. Butowski
2022Neuro-Oncology6 citations Open access
Semantic Scholar
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).
Dimitris G Placantonakis, Matthew Grabowski, T. C. Burns, N. Butowski +7 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).
M. Ahluwalia, M. Ciesielski, D. Reardon, N. Butowski +16 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
H. Colman, G. Lombardi, Eric T Wong, T. Walbert +25 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma
Jacob S. Young, N. Cho, Calixto-Hope G. Lucas, H. Najem +19 more
2025bioRxiv4 citations Open access
Semantic Scholar
TIPS-17 A FIRST-IN-HUMAN FEASIBILITY STUDY TO EVALUATE THE SAFETY OF SELECTIVE INTRA-ARTERIAL YTTRIUM-90 MICROSPHERE TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA (THE FRONTIER TRIAL)
S. Mouli, P. Goyal, Matthew C. Tate, K. Dixit +8 more
2023Neuro-Oncology Advances4 citations Open access
Semantic Scholar
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival
Eduardo Rodriguez-Almaraz, G. Guerra, N. Al-Adli, J. Young +20 more
2025Neuro-Oncology Advances3 citations Open access
Semantic Scholar
CTNI-76. A PHASE 1/2 DOSE ESCALATION AND EXPANSION STUDY OF SONODYNAMIC THERAPY WITH SONALA-001 IN COMBINATION WITH NON-ABLATIVE MR-GUIDED FOCUSED ULTRASOUND IN SUBJECTS WITH PROGRESSIVE OR RECURRENT GLIOBLASTOMA
Dimitris G Placantonakis, Mathew M. Grabowski, T. Burns, N. Butowski +5 more
2024Neuro-Oncology3 citations Open access
Semantic Scholar
TRLS-02. SAFETY AND EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394; PLX8394) IN CHILDREN AND ADULTS WITH RECURRENT, BRAF-ALTERED PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)
M. I. de la Fuente, N. Butowski, Jennie W. Taylor, R. Yaeger +14 more
2024Neuro-Oncology3 citations Open access
Semantic Scholar
LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
H. Colman, G. Lombardi, E. Wong, T. Walbert +24 more
2024Neuro-Oncology3 citations Open access
Semantic Scholar
Automatic Brain Tissue and Lesion Segmentation and Multi-Parametric Mapping of Contrast-Enhancing Gliomas without the Injection of Contrast Agents: A Preliminary Study
Jing Liu, A. Jakary, J. Villanueva-Meyer, N. Butowski +7 more
2024Cancers3 citations Open access
Semantic Scholar
CTNI-76. EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394) IN RECURRENT, PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)
M. I. de la Fuente, N. Butowski, Jennie W. Taylor, R. Yaeger +13 more
2023Neuro-Oncology3 citations Open access
Semantic Scholar
CTIM-06. A PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GLIOBLASTOMA: EXPLORING THE PROGNOSTIC VALUE OF TREATMENT-INDUCED CD8+CD57+ T-CELLS AS A MARKER FOR SURVIVAL
D. Peereboom, R. Lindsay, M. Badruddoja, L. Nabors +16 more
2023Neuro-Oncology3 citations Open access
Semantic Scholar
P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
M. Ahluwalia, M. Ciesielski, A. Abad, D. Reardon +17 more
2023Neuro-Oncology3 citations
Semantic Scholar
CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM)
F. Iwamoto, V. Gondi, N. Butowski, G. Falchook +13 more
2022Neuro-Oncology3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. A. Oberheim Bush×12
Invite
N. A. Oberheim Bush — researcher profile on SciRah
Jennie W. Taylor×11
Invite
Jennie W. Taylor — researcher profile on SciRah
J. Villanueva-Meyer×10
Invite
J. Villanueva-Meyer — researcher profile on SciRah
M. Aghi×9
Invite
M. Aghi — researcher profile on SciRah

×8

Invite

D. Solomon — researcher profile on SciRah

Invite

D. Raleigh — researcher profile on SciRah

Invite

A. Shai — researcher profile on SciRah

Invite

J. Phillips — researcher profile on SciRah

Susan M. Chang×6

Invite

Susan M. Chang — researcher profile on SciRah

Invite

A. Molinaro — researcher profile on SciRah

J. D. de Groot×6

Invite

J. D. de Groot — researcher profile on SciRah

Jennifer L. Clarke×6

Invite

Jennifer L. Clarke — researcher profile on SciRah